iData Insights

Soft Tissue Sarcoma - Pipeline Review, H2 2015 Now Available at iData Insights

Press Release   •   Jan 23, 2016 14:29 IST

Soft Tissue Sarcoma - Pipeline Review, H2 2015 Summary Global Markets Direct s, Soft Tissue Sarcoma - Pipeline Review, H2 2015, provides an overview of the Soft Tissue Sarcomas therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Soft Tissue Sarcoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Soft Tissue Sarcoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Soft Tissue Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Soft Tissue Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Soft Tissue Sarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Soft Tissue Sarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @

To Get Sample Copy of Report visit @

Table of Contents

Introduction 9

Global Markets Direct Report Coverage 9

Soft Tissue Sarcoma Overview 10

Therapeutics Development 11

Pipeline Products for Soft Tissue Sarcoma - Overview 11

Pipeline Products for Soft Tissue Sarcoma - Comparative Analysis 12

Soft Tissue Sarcoma - Therapeutics under Development by Companies 13

Soft Tissue Sarcoma - Therapeutics under Investigation by Universities/Institutes 18

Soft Tissue Sarcoma - Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Unknown Stage Products 22

Soft Tissue Sarcoma - Products under Development by Companies 23

Soft Tissue Sarcoma - Products under Investigation by Universities/Institutes 29

Soft Tissue Sarcoma - Companies Involved in Therapeutics Development 30

A. Menarini Industrie Farmaceutiche Riunite Srl 30

Advanced Proteome Therapeutics Corporation 31

Advenchen Laboratories, LLC 32

Altor BioScience Corporation 33

Amgen Inc. 34

Arog Pharmaceuticals, Inc. 35

Bayer AG 36

Bellicum Pharmaceuticals, Inc. 37

Boehringer Ingelheim GmbH 38

CASI Pharmaceuticals Inc. 39

Celgene Corporation 40

Cell Medica Limited 41

Cellceutix Corporation 42

Cellectar Biosciences, Inc. 43

CytRx Corporation 44

Daiichi Sankyo Company, Limited 45

Double Bond Pharmaceutical International AB 46

Eisai Co., Ltd. 47

Eli Lilly and Company 48

EpiZyme, Inc. 49

Exelixis, Inc. 50

F. Hoffmann-La Roche Ltd. 51

Gem Pharmaceuticals, LLC 52

GlaxoSmithKline Plc 53

Immune Design Corp. 54

Karyopharm Therapeutics, Inc. 55

Loxo Oncology, Inc. 56

Lytix Biopharma AS 57

MedImmune, LLC 58

Merck & Co., Inc. 59

Merrimack Pharmaceuticals, Inc. 60

Mirati Therapeutics Inc. 61

MolMed S.p.A. 62

Morphotek, Inc. 63

Northwest Biotherapeutics, Inc. 64

Novartis AG 65

Noxxon Pharma AG 66

OncoTherapy Science, Inc. 67

Onxeo SA 68

Pfizer Inc. 69

Pharma Mar, S.A. 70

Philogen S.p.A. 71

Plexxikon Inc. 72

Polaris Pharmaceuticals, Inc. 73

Recombio S.L 74

Rigontec GmbH 75

Sanofi 76

Shionogi & Co., Ltd. 77

Siena Biotech S.p.A. 78

Sigma-Tau S.p.A. 79

Sumitomo Dainippon Pharma Co., Ltd. 80

Targovax AS 81

Threshold Pharmaceuticals, Inc. 82

TRACON Pharmaceuticals, Inc. 83

Vicore Pharma AB 84

Soft Tissue Sarcoma - Therapeutics Assessment 85

Assessment by Monotherapy Products 85

Assessment by Combination Products 86

Assessment by Target 87

Assessment by Mechanism of Action 94

Assessment by Route of Administration 99

Assessment by Molecule Type 101

Drug Profiles 103

afatinib dimaleate - Drug Profile 103

AL-3818 - Drug Profile 108

aldoxorubicin hydrochloride - Drug Profile 110

ALT-836 - Drug Profile 113

APC-103 - Drug Profile 115

belinostat - Drug Profile 116

BI-853520 - Drug Profile 119

C-21 - Drug Profile 120

cabazitaxel - Drug Profile 122

cabozantinib s-malate - Drug Profile 124

cancer vaccine - Drug Profile 128

Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 129

Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 130

celyvir - Drug Profile 132

CMD-003 - Drug Profile 134

crenolanib besylate - Drug Profile 136

DCVax-Direct - Drug Profile 138

Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 139

Dendritic Cells + Cytokine Induced Killer Cells - Drug Profile 140

DSR-6434 - Drug Profile 141

durvalumab + tremelimumab - Drug Profile 142

efatutazone - Drug Profile 144

emactuzumab - Drug Profile 146

ENMD-2076 - Drug Profile 147

eribulin mesylate - Drug Profile 149

everolimus - Drug Profile 155

evofosfamide - Drug Profile 161

Fibromun - Drug Profile 169

G-100 - Drug Profile 171

GPX-150 - Drug Profile 173

GSK-3174998 - Drug Profile 176

HDM-201 - Drug Profile 177

I131-CLR1404 - Drug Profile 178

ID-LV305 + ID-G305 - Drug Profile 180

ImOl-100 - Drug Profile 182

irinotecan hydrochloride - Drug Profile 183

KM-3174 - Drug Profile 186

KRA-0008 - Drug Profile 190

LK-3 - Drug Profile 191

LOXO-101 - Drug Profile 192

LTX-315 - Drug Profile 194

LV-305 - Drug Profile 196

MAT-303 - Drug Profile 197

mocetinostat - Drug Profile 198

MVXONCO-1 - Drug Profile 201

NGR-hTNF - Drug Profile 202

NOV-110501 - Drug Profile 206

NOXS-93 - Drug Profile 207

olaratumab - Drug Profile 208

ONCOS-102 - Drug Profile 211

ontuxizumab - Drug Profile 213

OTSA-101 - Drug Profile 215

paclitaxel albumin bound - Drug Profile 216

palbociclib - Drug Profile 220

panobinostat - Drug Profile 224

pazopanib hydrochloride - Drug Profile 230

pembrolizumab - Drug Profile 236

Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 245

PF-03084014 - Drug Profile 247

PLX-7486 - Drug Profile 249

regorafenib - Drug Profile 250

ribociclib - Drug Profile 254

roneparstat - Drug Profile 257

S-588410 - Drug Profile 258

SA-083 - Drug Profile 259

sabarubicin - Drug Profile 260

selinexor - Drug Profile 262

SEN-461 - Drug Profile 268

talimogene laherparepvec - Drug Profile 269

tazemetostat - Drug Profile 272

TNF-PEG 20 - Drug Profile 274

trabectedin - Drug Profile 275

TRC-105 - Drug Profile 280

Vaccine for Soft Tissue Sarcoma - Drug Profile 283

vorinostat - Drug Profile 284

Soft Tissue Sarcoma - Recent Pipeline Updates 288

Soft Tissue Sarcoma - Dormant Projects 449

Soft Tissue Sarcoma - Discontinued Products 453

Soft Tissue Sarcoma - Product Development Milestones 454

Featured News & Press Releases 454

Appendix 463

Methodology 463

Coverage 463

Secondary Research 463

Primary Research 463

Expert Panel Validation 463

Contact Us 463

Disclaimer 464

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects